Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis
Gooderham M, Bunick C, Kircik L, Lynde C, Skov L, Blau J, Zhang W, Uy J, Winkelman W, Thaçi D. Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s442. DOI: 10.25251/skin.8.supp.442.Peer-Reviewed Original ResearchPhase 2b trialLaboratory parametersPlaque psoriasisCommon Terminology Criteria for Adverse Events grade 1Adverse Events grade 1Mild to moderate elevationMean triglyceride valuesPhase 3 studyAssessment of laboratory parametersAssociated with rhabdomyolysisTyrosine kinase 2 inhibitorCreatine kinaseJanus kinaseSerum cholesterol levelsDouble-blindPrimary endpointPsoriasis AreaCK elevationStudy treatmentLipid parametersTriglyceride valuesGrade 1PsoriasisCholesterol levelsPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply